With many nations facing the Omicron variant threat of the coronavirus, the Serum Institute of India, the manufacturer of Covishield vaccine, has been directed by the Subject Expert Committee to conduct a clinical trial for a booster dose among the Indian population. The data thereafter submitted by the SII will be used to determine whether a booster dose will be green-lit in the country.